The J-ALEX trial—is frontline alectinib a new standard of care?

New-Generation Anaplastic Lymphoma Kinase Inhibitor Experience in a Case With Non–Small Cell Lung Cancer: High Efficacy but Unexpected Toxicity

“…8 Alectinib is a potent ALK inhibitor used in these cases as first- and second-line choice. 9 We could not use alectinib for our patient because of reimbursement problem. Lorlatinib is a novel, oral, reversible, ATP-competitive macrocyclic TKI that targets ALK and ROS1 .…”